FeaturedOncology

Inavolisib (Itovebi)

Genentech / Roche

PI3Kα inhibitor. FDA approved. INAVO120 OS analysis at ASCO 2025 confirmed significant OS improvement in PIK3CA-mutant HR+/HER2- breast cancer.

HR+ HER2- Breast Cancer

Linked Studies

NCT04191499PrimaryACTIVE_NOT_RECRUITINGPHASE2, PHASE3

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Breast CancerUpdated Mar 2026

Loading comments…

Also Known As

Other names

inavolisib

Search all trials →Request coverage update